Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Lung cancer disease

Human Odor, visibility, nasopharyngeal and eye irritation Acute respiratory disease Chronic respiratory disease, lung cancer... [Pg.55]

Effects of indoor air pollutants on humans are essentially the same as those described in Chapter 7. However, there can be some additional pollutant exposures in the indoor environment that are not common in the ambient setting. From the listing in Table 23-1, radon exposures indoors present a radiation hazard for the development of lung cancer. Environmental tobacco smoke has been found to cause lung cancer and other respiratory diseases. Biological agents such as molds and other toxins may be a more likely exposure hazard indoors than outside. [Pg.388]

At typical indoor concentrations, COj is not thought to be a direct cause of adverse health effects however, COj is an easily-measured surrogate for other occupant-generated pollutants. Eye, nose, and throat irritation headaches lung cancer may contribute to heart disease buildup of fluid in the middle ear increased severity and frequency of asthma episodes decreased lung function. ETS is also a source of odor and irritation complaints. [Pg.56]

Nitrogen mustard is clinically used for the treatment of lymphomas and some forms of lung cancer. The major indication for mechlorethamine is Hodgkin s disease as a part of the MOPP regimen (mechlorethamine + vincristine (oncovin) + procarbazine + prednisone). The usual dose consists of 6 mg/m2 on days 1 and 8. This drug has pronounced hematological toxicity (myelo-suppression). [Pg.54]

These arotinoids, which were first introduced for the treatment of skin diseases, may also have potential as anticancer diugs. For example, the synthetic retinoid 6-[3-(l-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) has been shown to induce apoptosis in a variety of cancer cells including lung cancer cells in vitro, and studies concerning the use of this agent in vivo would be desirable. [Pg.1073]

Scitovsky et al. (1986) calculated the average cost per AIDS-related hospital admission as US 9,024 ranging from US 7,026 to US 23,425. A more comprehensive picture is presented by Scitovsky and Rice (1987), who estimated provider cost of the AIDS epidemic in the United States in 1985, 1986, and 1991, based on prevalence estimates provided by the Center for Disease Control (CDC). They predicted that the core provider costs of AIDS would rise from US 630 million in 1985 to US 1.1 billion in 1986 and to US 8.5 billion in 1991. The authors compared their estimates of the cost of AIDS in the USA with the estimates for end-stage renal disease (US 2.2 billion), traffic accidents (US 5.6 billion), lung cancer (US 2.7 billion), and breast cancer (US 2.2 billion). They concluded that the core provider costs of AIDS were relatively low in comparison with the provider costs of all illness as well as the costs of these other diseases. However, they also assessed the non-care costs (e.g., for research) to rise from US 319 million in 1985 to US 542 million in 1986 and to US 2.3 billion in 1991. [Pg.354]

The a-tocopherol, P-carotene (ATBC) Cancer Prevention study was a randomised-controlled trial that tested the effects of daily doses of either 50 mg (50 lU) vitamin E (all-racemic a-tocopherol acetate), or 20 mg of P-carotene, or both with that of a placebo, in a population of more than 29,000 male smokers for 5-8 years. No reduction in lung cancer or major coronary events was observed with any of the treatments. What was more startling was the unexpected increases in risk of death from lung cancer and ischemic heart disease with P-carotene supplementation (ATBC Cancer Prevention Study Group, 1994). Increases in the risk of both lung cancer and cardiovascular disease mortality were also observed in the P-carotene and Retinol Efficacy Trial (CARET), which tested the effects of combined treatment with 30 mg/d P-carotene and retinyl pahnitate (25,000 lU/d) in 18,000 men and women with a history of cigarette smoking or occupational exposure to asbestos (Hennekens et al, 1996). [Pg.33]

OMENN G S, GOODMAN G E, THORNQUIST M D, BALMES J, CULLEN M R, GLASS A, KEOGH J P, MEYSKENS F L, VALANIS B, WILLIAMS J H, BARNHART S and HAMMAR S (1996) Effects of a combination of beta-carotene and vitamin A on lung cancer and cardiovascular disease. N EnglJ Med 1150-1155. [Pg.125]

The First International Symposium on Disease Prevention by IP6 and other Rice Bran Components. was conducted in Kyoto, Japan on June 8-9, 1998. Scientists from all over the globe gathered and presented their research findings on the effect of IP6 and other rice bran components on several aspects of health. The brain storming sessions of nearly 35 presentations demonstrated that IP6 is a chemopreventive agent as both a cancer inhibitor and a cancer suppressor in mammary gland, colon and lung cancer (Shamsuddin et al, 1997). [Pg.360]

Pulmonary disease, small-cell lung cancer, head trauma, stroke, central nervous system infections, pituitary surgery, prolactinoma, severe nausea, psychiatric disease, and postoperative state... [Pg.169]

Father with emphysema and lung cancer. There is no family history of type 2 diabetes or heart disease... [Pg.239]

Explain the pathologic progression of lung cancer and its relationship with signs and symptoms of the disease. [Pg.1323]

The signs and symptoms of lung cancer can be classified as pulmonary, extrapulmonary, and paraneoplastic. These classifications relate to disease progression. [Pg.1323]

The treatment goals in lung cancer are cure (early-stage disease), prolongation of survival, and maintenance or improvement of quality of life through alleviation of symptoms. [Pg.1323]


See other pages where Lung cancer disease is mentioned: [Pg.481]    [Pg.452]    [Pg.239]    [Pg.241]    [Pg.481]    [Pg.452]    [Pg.239]    [Pg.241]    [Pg.381]    [Pg.537]    [Pg.356]    [Pg.356]    [Pg.393]    [Pg.439]    [Pg.59]    [Pg.389]    [Pg.42]    [Pg.43]    [Pg.295]    [Pg.324]    [Pg.325]    [Pg.325]    [Pg.56]    [Pg.193]    [Pg.569]    [Pg.1276]    [Pg.331]    [Pg.55]    [Pg.148]    [Pg.150]    [Pg.34]    [Pg.39]    [Pg.54]    [Pg.230]    [Pg.190]    [Pg.108]    [Pg.1216]    [Pg.1295]    [Pg.1323]   
See also in sourсe #XX -- [ Pg.781 ]




SEARCH



Diseases cancer

Lung cancer

Lung disease lungs

© 2024 chempedia.info